Key Points
- Insider selling: Zhenyu Xu sold 10,000 SOPHiA GENETICS shares at $8.91 each for $89,100 under a Rule 10b5-1 plan, reducing the position by 1.76% to 556,887 shares. Xu has also sold shares in several transactions since early July.
- Recent performance and earnings: SOPH opened at $8.40, near its one-year high of $8.98, compared with a 50-day moving average of $6.58. Its latest quarterly loss of $0.26 per share missed estimates, though revenue of $23.31 million exceeded expectations.
- Analyst outlook remains mixed: Analysts have issued three Buy, one Hold and one Sell rating, producing an overall “Hold” consensus and an average price target of $10.00. Institutional investors own 31.59% of the company.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 10,000 shares of the company's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $8.91, for a total value of $89,100.00. Following the completion of the transaction, the insider directly owned 556,887 shares of the company's stock, valued at $4,961,863.17. The trade was a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Zhenyu Xu also recently made the following trade(s):
- On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total value of $30,080.00.
- On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.29, for a total value of $123,930.00.
- On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.00, for a total value of $21,000.00.
- On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $69,200.00.
- On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $22,800.00.
- On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total value of $38,221.81.
SOPHiA GENETICS Price Performance
Shares of NASDAQ SOPH opened at $8.40 on Tuesday. The firm has a market cap of $704.68 million, a PE ratio of -7.30 and a beta of 0.96. The firm has a fifty day moving average of $6.58 and a 200 day moving average of $5.48. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a one year low of $3.10 and a one year high of $8.98.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.
Institutional Investors Weigh In On SOPHiA GENETICS
Hedge funds have recently modified their holdings of the business. AXQ Capital LP purchased a new position in shares of SOPHiA GENETICS in the second quarter worth about $119,000. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS during the second quarter worth about $9,809,000. Hennion & Walsh Asset Management Inc. purchased a new stake in SOPHiA GENETICS during the 2nd quarter valued at about $567,000. Royal Bank of Canada grew its stake in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock valued at $96,000 after acquiring an additional 18,781 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the 1st quarter valued at about $1,772,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. Finally, BTIG Research increased their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $10.00.
View Our Latest Analysis on SOPH
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
